AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA...

Related Keywords

Puerto Rico ,United States ,Amsterdam ,Noord Holland ,Netherlands ,Colorado ,America ,Arterioscler Thromb Vasc ,Clin Lipidol ,Jessica Akopyan ,Johns Hopkins ,Coll Cardiol ,C Michael Gibson ,Prnewswire Amgen ,Michellel Odonoghue ,Justin Claeys ,Paul Burton ,Teneobio Inc ,Beigene Ltd ,Exchange Commission ,Nasdaq ,Amgen ,Institute Of Clinical Research ,Drug Administration ,Harvard Medical School ,Linkedin ,Extension Program On Long ,European Society Of Cardiology ,Twitter ,Awareness To Action Implementation Consortium ,Instagram ,Youtube ,Chemocentryx Inc ,University Of Colorado ,Kyowa Kirin Co Ltd ,Innovative Lipid Management ,Olpasiran Phase ,Demonstrates Continued Reduction ,Year After ,Action Implementation Consortium ,Late Breaking Science Session ,European Society ,Annual Meeting ,Cardiovascular Medicine ,Action Implementation ,Clinical Research ,Oxidized Phospholipids ,Primary Results ,Long Term Efficacy ,Coronary Artery Disease ,Elevated Lipoprotein ,Outcomes Trial ,Sponsored Studies ,Major Adverse Limb Events ,Stable Atherosclerotic Vascular Disease ,Olpasiran Trials ,Cardiovascular Events And Lipoprotein ,Dow Jones Industrial Average ,Horizon Therapeutics ,Federal Trade Commission ,Thromb Vasc ,